There are many active research projects accessing and applying shared ADNI data. Use the search above to find specific research focuses on the active ADNI investigations. This information is requested annually as a requirement for data access.
| Principal Investigator | |
| Principal Investigator's Name: | Dunia Alhamad |
| Institution: | The University of Sheffield |
| Department: | Neuroscience |
| Country: | |
| Proposed Analysis: | Dementia is a significant public health challenge that results in impairment in multiple cognitive domains which results in impairment of normal daily activities. Moreover, Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB) are dementia subtypes. Additionally, both conditions have an early stage of the disease called mild cognitive impairment (MCI), during which clinical symptoms are ambiguous and difficult to differentiate. Accordingly, we are interested in using magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging biomarkers to provide a differential diagnosis for MCI-AD and MCI-LB. Moreover, we aimed to focus on investigating cortical thickness, amyloid-beta deposition, neurovascular damage, and neuroinflammation. Additionally, we aimed to use T1-MPRAGE, FLAIR, T2, resting state, ASL, and DTI sequences to investigate different disease biomarkers. |
| Additional Investigators | |
| Investigator's Name: | Li Su |
| Proposed Analysis: | Dementia is a significant public health challenge that results in impairment in multiple cognitive domains which results in impairment of normal daily activities. Moreover, Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB) are dementia subtypes. Additionally, both conditions have an early stage of the disease called mild cognitive impairment (MCI), during which clinical symptoms are ambiguous and difficult to differentiate. Accordingly, we are interested in using magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging biomarkers to provide a differential diagnosis for MCI-AD and MCI-LB. Moreover, we aimed to focus on investigating cortical thickness, amyloid-beta deposition, neurovascular damage, and neuroinflammation. Additionally, we aimed to use T1-MPRAGE, FLAIR, T2, resting state, ASL, and DTI sequences to investigate different disease biomarkers. |
| Investigator's Name: | Sheharyar Baig |
| Proposed Analysis: | Dementia is a significant public health challenge that results in impairment in multiple cognitive domains which results in impairment of normal daily activities. Moreover, Alzheimer’s disease (AD) and Dementia with Lewy Bodies (DLB) are dementia subtypes. Additionally, both conditions have an early stage of the disease called mild cognitive impairment (MCI), during which clinical symptoms are ambiguous and difficult to differentiate. Accordingly, we are interested in using magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging biomarkers to provide a differential diagnosis for MCI-AD and MCI-LB. Moreover, we aimed to focus on investigating cortical thickness, amyloid-beta deposition, neurovascular damage, and neuroinflammation. Additionally, we aimed to use T1-MPRAGE, FLAIR, T2, resting state, ASL, and DTI sequences to investigate different disease biomarkers. |
